Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres

MLA

Costantino Zampaletta, et al. “Effectiveness and Safety of Infliximab and Adalimumab for Ambulatory Crohn’s Disease Patients in Primary Gastroenterology Centres.” European Journal of Internal Medicine, vol. 25, June 2014, pp. 485–90. EBSCOhost, https://doi.org/10.1016/j.ejim.2014.02.010.

APA

Costantino Zampaletta, GianMarco Giorgetti, Giorgio Pelecca, Walter Elisei, P.G. Lecca, Roberto Faggiani, Giacomo Forti, Giovanni Brandimarte, Antonio Tursi, Marcello Picchio, & Antonio Penna. (2014). Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn’s disease patients in primary gastroenterology centres. European Journal of Internal Medicine, 25, 485–490. https://doi.org/10.1016/j.ejim.2014.02.010

Chicago

Costantino Zampaletta, GianMarco Giorgetti, Giorgio Pelecca, Walter Elisei, P.G. Lecca, Roberto Faggiani, Giacomo Forti, et al. 2014. “Effectiveness and Safety of Infliximab and Adalimumab for Ambulatory Crohn’s Disease Patients in Primary Gastroenterology Centres.” European Journal of Internal Medicine 25 (June): 485–90. doi:10.1016/j.ejim.2014.02.010.